Home / Recalls / Rubicon Research Private Limited / D-0362-2022

D-0362-2022 Class II Terminated

Recalled by Rubicon Research Private Limited — Ambernath, N/A

FDA drug recall D-0362-2022 was initiated by Rubicon Research Private Limited on Dec 31, 2021 and is designated Class II. Reason for recall: Complaint received of foreign matter (metal) embedded in tablet. The recall status is terminated (terminated Nov 4, 2022). Affected quantity: 3,684 1000-count bottles.

Recall details

Product Type: Drugs
Report Date: Jan 19, 2022
Initiation Date: Dec 31, 2021
Termination Date: Nov 4, 2022
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 3,684 1000-count bottles

Product description

Metoprolol Tartrate Tablets, USP 25 mg, 1000 - count bottle, Rx Only, Distributed by: TruPharma, LLC. Tampa, FL 33609; Manufactured by: Rubicon Research Prvate Limited Ambernath, Dist. Thane, 421506 India. NDC 52817-360-00

Reason for recall

Complaint received of foreign matter (metal) embedded in tablet.

Distribution pattern

Product was distributed to one distributor who may have distributed the product further nationwide.

Code information

Batch # 210211H1, Exp. date FEB 2024

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-0362-2022
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.